Search

How to apply for an EHA Research Grant

On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.

Read more

EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.

Read more

EHA Research Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

What an EHA Research Grant supports

Our EHA Research Grants support basic and translational lab-based research in hematology.

Read more

What an EHA Bilateral Collaborative Grant supports

Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.

Read more

Highlights from the SWG

Session on thrombocytopenias and platelet function disordersFull title‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia. ’

DateThe session took place as part of the EHA 2023 Congress. This was held from June 8–11, 2023.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2019

Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs: 
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)

EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more